Amniotics joins Vinnova funded ’CAMP’ to improve outcome of lung transplantations with PulmoStem™
December 20, 2021
Amniotics AB (publ) (Nasdaq Stockholm: AMNI), a developer of novel cell therapy products, today announced that it has joined the research project Centre for Advanced Medical Products (CAMP), a consortium funded by a SEK 48 million grant from the Swedish innovation agency Vinnova. In this partnership they will work to improve the outcome of lung transplantations using Amniotics’ stem cell therapy product PulmoStem™.
CAMP is working nationally to build infrastructures and technologies to pave the way for development and commercialization of efficacious gene and cell therapy pharmaceuticals, known as Advanced Therapy Medicinal Products (ATMPs) in the EU. To realize the potential of ATMPs for patients and society, CAMP works to build stronger partnerships between universities, healthcare and industry to ensure effective translation of Swedish research.
“Lung transplantation is the only option for end-stage lung disease. However, only 20 percent of donated lungs are usable for transplantation. The collaboration with CAMP will provide valuable scientific capabilities in our work to show that PulmoStem™ is able to restore damaged and discarded donor lungs and thereby significantly increase the number of lungs available for transplantation,” says Amniotics’ CEO Kåre Engkilde. “We have worked together with Professor Sandra Lindstedt Ingemansson this past year and look forward to expand our collaboration with her and her team at Skåne University Hospital through CAMP.”
“We believe that PulmoStem™ may be an important candidate to help patients suffering from Acute Lung Injury by making more donated lungs suited for transplantation and we are grateful to be able to continue our work with Amniotics and the organization of CAMP to investigate this further,” says Professor Sandra Lindstedt Ingemansson, Skåne University Hospital.
“Amniotics will be a great addition to the CAMP family. Their clinical experience during the pandemic gives them a unique position to accelerate ATMP based solutions to patients with lung disorders for which treatment options are currently limited. We look forward to working with Amniotics on the ‘Amniotic derived cell therapy improving outcome in lung transplantation’ project’, says Jukka Lausmaa, Centre Director at CAMP.